article thumbnail

Exploring the Miracle Antibody Drug Conjugate Technologies

Roots Analysis

Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment. This trend is expected to continue in the foreseeable future.

article thumbnail

Beyond the Pill: The Rise of Biologics and the Evolution of Pharmaceutical Therapies

Cloudbyz

Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology. Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins.

Gene 74
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leading innovators in gene splicing using nucleases for the pharmaceutical industry

Pharmaceutical Technology

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

article thumbnail

TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress

The Pharma Data

Hereditary angioedema is a lifelong condition and research shows that concerns about another attack can limit the way patients lead their lives,” said Prof. TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. percent (-100; 852.8), and the median reduction was 97.7 Markus Magerl, M.D.,